Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Mark J. Vignola Sells 8,129 Shares

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Mark J. Vignola sold 8,129 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $5.72, for a total value of $46,497.88. Following the completion of the transaction, the chief financial officer now owns 83,811 shares of the company’s stock, valued at approximately $479,398.92. The trade was a 8.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Terns Pharmaceuticals Price Performance

TERN opened at $5.24 on Thursday. The firm has a fifty day moving average price of $6.29 and a 200 day moving average price of $7.38. Terns Pharmaceuticals, Inc. has a 1 year low of $4.32 and a 1 year high of $11.40. The stock has a market cap of $445.08 million, a P/E ratio of -4.44 and a beta of -0.31.

Terns Pharmaceuticals (NASDAQ:TERN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.05. Equities analysts expect that Terns Pharmaceuticals, Inc. will post -1.19 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on TERN shares. BMO Capital Markets reissued an “outperform” rating and set a $26.00 price target (up from $19.00) on shares of Terns Pharmaceuticals in a research report on Monday, September 16th. JMP Securities reissued a “market outperform” rating and set a $20.00 target price on shares of Terns Pharmaceuticals in a report on Wednesday, December 4th. Oppenheimer upped their price target on shares of Terns Pharmaceuticals from $17.00 to $20.00 and gave the company an “outperform” rating in a report on Wednesday, December 4th. Finally, HC Wainwright reiterated a “neutral” rating and set a $7.50 price objective on shares of Terns Pharmaceuticals in a research note on Wednesday, December 4th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Terns Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $18.30.

Hedge Funds Weigh In On Terns Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Virtu Financial LLC increased its position in shares of Terns Pharmaceuticals by 110.2% in the third quarter. Virtu Financial LLC now owns 62,216 shares of the company’s stock valued at $519,000 after buying an additional 32,624 shares in the last quarter. Geode Capital Management LLC grew its stake in Terns Pharmaceuticals by 7.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,207,479 shares of the company’s stock valued at $10,072,000 after acquiring an additional 85,617 shares during the period. XTX Topco Ltd purchased a new stake in Terns Pharmaceuticals in the 3rd quarter worth $148,000. Point72 Asset Management L.P. raised its position in Terns Pharmaceuticals by 0.6% during the third quarter. Point72 Asset Management L.P. now owns 2,707,515 shares of the company’s stock worth $22,581,000 after acquiring an additional 17,139 shares during the period. Finally, Polymer Capital Management HK LTD purchased a new position in Terns Pharmaceuticals during the third quarter valued at $200,000. Hedge funds and other institutional investors own 98.26% of the company’s stock.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.